Smith Group Asset Management LLC Invests $840,000 in Bristol Myers Squibb Company $BMY

Smith Group Asset Management LLC acquired a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 13,850 shares of the biopharmaceutical company’s stock, valued at approximately $840,000.

A number of other large investors have also recently bought and sold shares of the business. Swiss RE Ltd. bought a new position in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $25,000. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $25,000. Physician Wealth Advisors Inc. lifted its holdings in shares of Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares during the last quarter. Bayban acquired a new position in Bristol Myers Squibb during the 4th quarter valued at approximately $31,000. Finally, EQ Wealth Advisors LLC bought a new position in Bristol Myers Squibb during the 4th quarter worth $32,000. Institutional investors own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on BMY. Raymond James Financial reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday. UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday. Finally, Guggenheim reissued a “buy” rating and set a $72.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Eight analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and an average price target of $61.25.

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $63.65 on Wednesday. The stock has a market cap of $129.97 billion, a P/E ratio of 17.88, a P/E/G ratio of 0.18 and a beta of 0.23. The firm’s 50-day simple moving average is $57.70 and its 200 day simple moving average is $58.17. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $64.96. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion during the quarter, compared to analyst estimates of $10.93 billion. During the same quarter in the prior year, the firm posted $1.80 EPS. Bristol Myers Squibb’s revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts expect that Bristol Myers Squibb Company will post 6.34 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 70.79%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.